Pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma is now fully approved.
FDA Approvals
Pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma is now fully approved.
FDA Approvals